ARTICANZ - Beta (ver 0.9)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - location/TAS/7000-Hobart-Royal-Hobart-Hospital
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
30
trial(s) found.
NCT06868277
Advanced
Phase 3
Recruiting
A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab Monotherapy for the First-line Treatment of Patients With PD-L1-high Metastatic Non-small Cell Lung Cancer (ARTEMIDE-Lung04) (
ARTEMIDELung04
)
anti-PD-1 monoclonal antibody
bispecific PD-1/TIGIT antibody
Non-small cell lung cancer
TAS
7000 - Hobart - Royal Hobart Hospital
NCT06764485
Advanced
Phase 3
Recruiting
A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 Versus Investigator's Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) -
rechARge
dual AR degrader antagonist
taxane
Castrate-resistant prostate cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2076 - Wahroonga - Sydney Adventist Hospital
2109 - North Ryde - Macquarie University Hospital
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
2560 - Campbelltown - Macarthur Cancer Therapy Centre - Campbelltown Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
QLD
4120 - Greenslopes - Greenslopes Private Hospital- Gallipoli Medical Research Foundation
4215 - Southport - Tasman Oncology
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5037 - Kurralta Park - Icon Cancer Centre Adelaide
5112 - Elizabeth Vale - Lyell McEwin Hospital
WA
6150 - Murdoch - Fiona Stanley Hospital
TAS
7000 - Hobart - Royal Hobart Hospital
NCT06588478
Haem
Phase 2
Recruiting
A Phase 2, Open-Label, Randomized Study Evaluating the Efficacy and Safety of 3 Doses of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Who Previously Received Treatment With a Covalent Bruton Tyrosine Kinase Inhibitor
BTK inhibitor
Chronic lymphocytic leukaemia
Small Lymphocytic Lymphoma
NSW
2200 - Bankstown - Bankstown-Lidcombe Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
3844 - Traralgon - Latrobe Regional Hospital
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
5042 - Bedford Park - Flinders Medical Centre
WA
6005 - West Perth - Perth Blood Institute
TAS
7000 - Hobart - Royal Hobart Hospital
NCT06284317
Curative
Phase 3
Recruiting
An International, Multicentre, Open-label Randomised Phase III Trial to Evaluate the Benefit of Adding Adjuvant Durvalumab After Neoadjuvant Chemotherapy Plus Durvalumab in Patients With Stage IIB-IIIB (N2) Resectable NSCLC (
ADOPT-lung
)
anti-PD-L1 monoclonal antibody
Non-small cell lung cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
TAS
7000 - Hobart - Royal Hobart Hospital
NCT06047080
Haem
Phase 3
Recruiting
A Phase III, Multicenter, Randomized, Open-Label Study Comparing the Efficacy and Safety of Glofitamab (RO7082859) in Combination With Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma (
GO44145
)
alkylating agent
anthracycline
anti-CD20 monoclonal antibody
anti-CD79b antibody-drug conjugate
bispecific T-cell engager,CD20-targeting
glucocorticoid
Diffuse large B-cell lymphoma
NSW
2031 - Randwick - Prince of Wales Hospital
2139 - Concord - Concord Repatriation General Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3065 - Fitzroy - St Vincent's Hospital Melbourne
3128 - Box Hill - Box Hill Hospital - Eastern Health
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4812 - Hyde Park - Icon Cancer Centre Townsville
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
TAS
7000 - Hobart - Royal Hobart Hospital
NCT06003621
Advanced
Phase 2
Recruiting
A Single Arm, Open-label, Phase II Signal-seeking Trial of Tiragolumab and Atezolizumab in Patients With Advanced Solid Tumours. (
MoST-TAP
)
anti-PD-L1 monoclonal antibody
anti-TIGIT monoclonal antibody
NOT Non-small cell lung cancer
Solid tumour
NSW
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute
2640 - Albury - Border Medical Oncology Research Unit
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit
VIC
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre
QLD
4350 - Toowoomba - Toowoomba Hospital
4700 - Rockhampton - Rockhampton Hospital
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
4870 - Cairns - Cairns Base Hospital
WA
6150 - Murdoch - Fiona Stanley Hospital
TAS
7000 - Hobart - Royal Hobart Hospital
NCT05730036
Haem
Phase 3
Recruiting
An Open-label, Randomized, Phase 3 Study of Linvoseltamab (REGN5458; Anti- BCMA x Anti-CD3 Bispecific Antibody) Versus the Combination of Elotuzumab, Pomalidomide, and Dexamethasone (EPd), in Patients With Relapsed/Refractory Multiple Myeloma (
LINKER-MM3
)
anti-CS1 monoclonal antibody
bispecific T-cell engager,BCMA-targeting
glucocorticoid
immunomodulatory imide drug
Multiple myeloma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
VIC
3066 - Epping - Northern Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - One Clinical Research
TAS
7000 - Hobart - Royal Hobart Hospital
7250 - Launceston - Launceston General Hospital - Northern Cancer Centre
NCT05611931
Advanced
Phase 3
Recruiting
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma (
XPORT-EC-042
)
XPO1 inhibitor
placebo
Endometrial cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
2305 - New Lambton Heights - Newcastle Private Hospital
2560 - Campbelltown - Macarthur Cancer Therapy Centre - Campbelltown Hospital
2640 - Albury - Border Medical Oncology Research Unit
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
3168 - Clayton - Monash Medical Centre
3199 - Frankston - Peninsula Health Frankston Hospital
3000 - Melbourne - Peter MacCallum Cancer Centre (WITHDRAWN)
QLD
4215 - Southport - ICON Cancer Care
4350 - Toowoomba - Toowoomba Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
TAS
7000 - Hobart - Royal Hobart Hospital
NCT05552976
Haem
Phase 3
Recruiting
A Phase 3, Two-stage, Randomized, Multicenter, Open-label Study Comparing Mezigdomide (CC-92480/BMS-986348), Carfilzomib, and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM):
SUCCESSOR-2
cereblon E3 ligase modulator
glucocorticoid
proteasome inhibitor
Multiple myeloma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
VIC
3002 - East Melbourne - Epworth Freemasons
3065 - Fitzroy - St Vincent's Hospital Melbourne
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
TAS
7000 - Hobart - Royal Hobart Hospital (WITHDRAWN)
NCT05514054
Curative
Phase 3
Recruiting
EMBER-4
: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients Who Have Previously Received 2 to 5 Years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer With an Increased Risk of Recurrence
selective estrogen receptor degrader
Breast cancer
NT
0810 - Tiwi, Royal Darwin Hospital - Northern Centre for Oncology
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2060 - North Sydney - Mater Hospital
2170 - Liverpool - Liverpool Hospital
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3066 - Epping - Northern Hospital
3128 - Box Hill - Box Hill Hospital - Eastern Health
3135 - Ringwood East - Maroondah Hospital
3168 - Clayton - Monash Medical Centre
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
3630 - Shepparton - Goulburn Valley Health
QLD
4215 - Southport - Gold Coast University Hospital
4655 - Urraween - Cancer Care Service, Hervey Bay Hospital
4740 - Mackay - Mackay Base Hospital
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5011 - Woodville South - The Queen Elizabeth Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
TAS
7000 - Hobart - Royal Hobart Hospital
7250 - Launceston - Launceston General Hospital - Northern Cancer Centre
NCT04594642
Haem
Phase 1
Recruiting
A Multicenter, Phase 1, Open-label, Dose-escalation and Expansion Study of AZD0486, a Bispecific Antibody Targeting CD19 in Subjects With B-Cell Non-Hodgkin Lymphoma (
D7400C00006
)
bispecific T-cell engager,CD19-targeting
Diffuse large B-cell lymphoma
Follicular lymphoma
High-grade B-cell lymphoma
Non-Hodgkin's lymphoma
VIC
3004 - Melbourne, Southbank - Alfred Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
SA
5042 - Bedford Park - Flinders Medical Centre
TAS
7000 - Hobart - Royal Hobart Hospital
NCT04576156
Haem
Phase 3
Recruiting
A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients With Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor (
MYF3001
)
telomerase inhibitor
Myelofibrosis
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
VIC
3121 - Richmond - Epworth Freemasons Hospital
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
TAS
7000 - Hobart - Royal Hobart Hospital
NCT04332822
Haem
Phase 3
Recruiting
R-MINI-CHOP Versus R-MINI-CHP in Combination With Polatuzumab-vedotin, as Primary Treatment for Patients With Diffuse Large B-cell Lymphoma, ≥80 Years, or Frail ≥75 Years - an Open Label Randomized Nordic Lymphoma Group Phase III Trial (
POLAR-BEAR
)
anti-CD79b antibody-drug conjugate
Diffuse large B-cell lymphoma
NSW
2031 - Randwick - Prince of Wales Hospital
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2139 - Concord - Concord Repatriation General Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute
2487 - Cudgen - Tweed Valley Hospital
2640 - Albury - Albury Wodonga Regional Cancer Centre
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit
ACT
2605 - Garran - The Canberra Hospital
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3065 - Fitzroy - St Vincent's Hospital Melbourne
3066 - Epping - Northern Hospital
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre
QLD
4575 - Birtinya - Sunshine Coast University Hospital
WA
6000 - Perth - Royal Perth Hospital
6150 - Murdoch - Fiona Stanley Hospital
TAS
7000 - Hobart - Royal Hobart Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NCT04170283
Haem
Phase 3
Enrolling by invitation
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies (
BGB-3111-LTE1
)
BTK inhibitor
B-cell malignancy
NOT Solid tumour
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2139 - Concord - Concord Repatriation General Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2217 - Kogarah - St George Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2640 - Albury - Border Medical Oncology Research Unit
ACT
2606 - Canberra - Paratus Clinical Research Woden
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
3168 - Clayton - Monash Medical Centre
3199 - Frankston - Peninsula Health Frankston Hospital
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
4102 - Woolloongabba - Princess Alexandra Hospital
4120 - Greenslopes - Brisbane Clinic For Lymphoma, Myeloma And Leukaemia
4224 - Tugun - Genesis Care Tugun - John Flynn Private Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5037 - Kurralta Park - Icon Cancer Centre Adelaide
5042 - Bedford Park - Flinders Medical Centre
WA
6000 - Perth - Royal Perth Hospital
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
TAS
7000 - Hobart - Royal Hobart Hospital
NZ
NZ.0622 - Takapuna - North Shore Hospital
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.3112 - Tauranga - Tauranga Hospital, Bay of Plenty Clinical Trials Unit
NZ.3210 - Hamilton - Waikato Hospital
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
ACTRN12623000620628
Haem
Phase 2
Recruiting
NHL38 Epco-Sandwich: A phase II multicentre, single arm, open-label trial of epcoritamab-containing combination salvage therapy followed by autologous stem cell transplantation and epcoritamab consolidation in patients with relapsed large B-cell lymphoma.
bispecific T-cell engager,CD20-targeting
Diffuse large B-cell lymphoma
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2139 - Concord - Concord Repatriation General Hospital
ACT
2605 - Garran - The Canberra Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3168 - Clayton - Monash Medical Centre
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
TAS
7000 - Hobart - Royal Hobart Hospital
ACTRN12623000096651
Advanced
Phase 2
Recruiting
LUMOS2
: Low & Anaplastic Grade Glioma Umbrella Study of Molecular Guided TherapieS
Cadonilimab
Niraparib
PARP inhibitor
PI3K-delta inhibitor
PI3K alpha inhibitor
PI3K inhibitor
Paxalisib
Selinexor
XPO1 inhibitor
bispecific PD-1/CTLA4 antibody
cancer therapy
cancer therapy,CTLA4-targeting
cancer therapy,PARP-targeting
cancer therapy,PD-1-targeting
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PI3K-delta-targeting
cancer therapy,PI3K-targeting
cancer therapy,PI3Kalpha-targeting
cancer therapy,XPO1-targeting
cancer therapy,mTOR-targeting
cancer therapy,mTORC1-targeting
cancer therapy,mTORC2-targeting
dual PI3K/mTOR inhibitor
immune checkpoint blockade
immune checkpoint blockade,CTLA4-targeting
immune checkpoint blockade,PD-1-targeting
immuno-oncology therapy,CTLA4-targeting
immuno-oncology therapy,PD-1-targeting
mTORC1/mTORC2 inhibitor
mTORC1 inhibitor
mTORC2 inhibitor
mTOR inhibitor
therapeutic modality,bispecific antibody
Anaplastic astrocytoma
Low-grade glioma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3066 - Epping - Northern Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
TAS
7000 - Hobart - Royal Hobart Hospital
ACTRN12622000973718
Advanced
Phase 2
Recruiting
SHERLOCK
: Phase 2 trial of sotorasib in combination with carboplatin-pemetrexed and bevacizumab-biosimilar as first line treatment for advanced non-squamous non-small cell lung cancer with KRAS G12C mutation
KRAS G12C/NRAS G12C/HRAS G12C inhibitor
anti-VEGF monoclonal antibody
antimetabolite
platinum-based antineoplastic agent
Non-small cell lung cancer
Non-squamous non-small-cell lung cancer
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2086 - Frenchs Forest - Northern Beaches Hospital
2170 - Liverpool - Liverpool Hospital
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4032 - Chermside - The Prince Charles Hospital
4575 - Birtinya - Sunshine Coast University Hospital
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5011 - Woodville South - The Queen Elizabeth Hospital
TAS
7000 - Hobart - Royal Hobart Hospital
ACTRN12622000856718
Haem
Phase 1 / Phase 2
Not yet recruiting
A Phase 1/2, First-in-Human, Multicenter, Open-Label, Dose Escalation and Dose-Expansion Study assessing safety and tolerability of Single-Agent ISB 1442 in Patients with Relapsed/Refractory Multiple Myeloma (
ISB-1442-101
)
bispecific CD38/CD47 antibody
Multiple myeloma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3004 - Melbourne, Southbank - Alfred Health
3066 - Epping - Northern Hospital
QLD
4215 - Southport - Gold Coast University Hospital
4217 - Benowa - Pindara Private Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
TAS
7000 - Hobart - Royal Hobart Hospital
ACTRN12622000180718
Curative
Not yet recruiting
Survival and Patterns of Care in the Era of FLOT-based Chemotherapy for Gastric and Gastroesophageal Adenocarcinoma (
SPACE-FLOT
): An international multicentre cohort study
Docetaxel
Fluorouracil
Leucovorin
Oxaliplatin
antimetabolite
cancer therapy
cytotoxic chemotherapy
fluoropyrimidine
platinum-based antineoplastic agent
taxane
Gastric adenocarcinoma
Gastric cancer
Gastroesophageal cancer
Gastroesophageal junction adenocarcinoma
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2200 - Bankstown - Bankstown-Lidcombe Hospital
ACT
2605 - Garran - The Canberra Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3011 - Footscray - Footscray Hospital
3066 - Epping - Northern Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
3168 - Clayton - Monash Medical Centre
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Flinders Medical Centre
5112 - Elizabeth Vale - Lyell McEwin Hospital
WA
6150 - Murdoch - Fiona Stanley Hospital
TAS
7000 - Hobart - Royal Hobart Hospital
7250 - Launceston - Launceston General Hospital - Northern Cancer Centre
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NZ.9016 - Dunedin - Dunedin Hospital
ACTRN12621000639820
Advanced
Phase 2
Recruiting
The activity and tolerability of Aromatase inhibitor plus PI3KCA inhibitor or CDK4/6 inhibitor in women with hormone receptor positive recurrent/metastatic gynaecological neoplasms (
PARAGON-II
) .
Alpelisib
CDK4/6 inhibitor
CDK4 inhibitor
CDK6 inhibitor
Letrozole
PI3K alpha inhibitor
Ribociclib
aromatase inhibitor
cancer therapy
cancer therapy,CDK4-targeting
cancer therapy,CDK6-targeting
cancer therapy,PI3Kalpha-targeting
endocrine therapy
endocrine therapy,oestrogen axis-targeting
oestrogen receptor-targeting therapy
Carcinoma
Endometrial cancer
Endometrial stromal sarcoma
Low-grade serous ovarian cancer
Ovarian cancer
Ovarian granulosa cell tumour
Platinum resistant high-grade epithelial cancers of fallopian tube
Platinum resistant ovarian cancer
Primary fallopian tube serous carcinoma
Uterine leiomyosarcoma
NSW
2031 - Randwick - Prince of Wales Hospital
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2305 - New Lambton Heights - Hunter New England Cancer Centre - John Hunter Hospital
2485 - Tweed Heads - The Tweed Hospital
2500 - Wollongong - Wollongong Hospital
2640 - Albury - Border Medical Oncology Research Unit
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
TAS
7000 - Hobart - Royal Hobart Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
ACTRN12621000507886
Haem
Phase 2
Recruiting
A single arm, open label, signal seeking, phase II trial of the activity of Durvalumab in combination with Acalabrutinib in patients with high-grade B cell lymphoma (
MoST-Addendum-15
)
BTK inhibitor
anti-PD-L1 monoclonal antibody
B-cell lymphoma
High-grade B-cell lymphoma
Lymphoma
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
TAS
7000 - Hobart - Royal Hobart Hospital
ACTRN12620000291987
Haem
Phase 3
Recruiting
An ALLG phase 3 randomised trial of Selinexor and Lenalidomide - versus Lenalidomide maintenance post Autologous Stem Cell Transplant for patients with Newly Diagnosed Multiple Myeloma (
SeaLAND
)
XPO1 inhibitor
immunomodulatory imide drug
Multiple myeloma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2139 - Concord - Concord Repatriation General Hospital
2480 - Lismore - Lismore Base Hospital
2640 - Albury - Border Medical Oncology Research Unit
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3011 - Footscray - Footscray Hospital
3066 - Epping - Northern Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
TAS
7000 - Hobart - Royal Hobart Hospital
7250 - Launceston - Launceston General Hospital - Northern Cancer Centre
ACTRN12619001199101
Haem
Phase 1 / Phase 2
Recruiting
Frailty-stratified, randomised controlled Bayesian adaptive trial of bortezomib versus lenalidomide in transplant-ineligible myeloma (TI-NDMM) – the
FRAIL-M
study
immunomodulatory imide drug
proteasome inhibitor
Multiple myeloma
NT
0810 - Tiwi, Royal Darwin Hospital - Northern Centre for Oncology
NA
2025 - Papatoetoe - Middlemore Hospital
NSW
2139 - Concord - Concord Repatriation General Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2340 - Tamworth - Tamworth Hospital-North West Cancer Centre
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
VIC
3004 - Melbourne, Southbank - Alfred Health
3011 - Footscray - Footscray Hospital
3021 - St Albans - Western Health - Sunshine Hospital
3066 - Epping - Northern Hospital
3844 - Traralgon - Latrobe Regional Hospital
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4350 - Toowoomba - Toowoomba Hospital
4575 - Birtinya - Sunshine Coast University Hospital
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5011 - Woodville South - The Queen Elizabeth Hospital
TAS
7000 - Hobart - Royal Hobart Hospital
NZ
NZ.0622 - Takapuna - North Shore Hospital
NZ.3112 - Tauranga - Tauranga Hospital, Bay of Plenty Clinical Trials Unit
NZ.4442 - Roslyn - Palmerston North Hospital Cancer Centre - Palmerston North Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NZ.9016 - Dunedin - Dunedin Hospital
ACTRN12619001185156
Advanced
Phase 2
Recruiting
A Phase II signal-seeking trial targeting recurrent high grade serous ovarian cancer (HGSC) with Cyclin E1 (CCNE1) over-expression with and without gene amplification to determine the clinical benefit rate. (
IGNITE
)
ATR inhibitor
Adavosertib
Ceralasertib
WEE1 inhibitor
cancer therapy
cancer therapy,ATR-targeting
cancer therapy,WEE1-targeting
High-grade serous carcinoma of the ovary, fallopian tube, and peritoneum
Ovarian cancer
Primary fallopian tube serous carcinoma
NSW
2031 - Randwick - Prince of Wales Hospital
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3021 - St Albans - Western Health - Sunshine Hospital
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
TAS
7000 - Hobart - Royal Hobart Hospital
ACTRN12619001031156
Haem
Phase 3
Recruiting
AMLM23- placebo-controlled study to compare the event free survival of patients receiving ivosidenib or enasidenib in patients with newly diagnosed acute myeloid leukemia or myelodysplastic syndrome. (
HOVON150-AMLSG29-18
)
IDH1 R132 inhibitor
IDH2 inhibitor
placebo
Acute myeloid leukaemia
Myelodysplastic syndrome
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2139 - Concord - Concord Repatriation General Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
3066 - Epping - Northern Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Flinders Medical Centre
WA
6000 - Perth - Royal Perth Hospital
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
6150 - Murdoch - Fiona Stanley Hospital
TAS
7000 - Hobart - Royal Hobart Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
ACTRN12619000280101
Haem
Phase 2
Recruiting
AMLM22/D2-The International Acute myeloid leukaemia (AML) Platform Consortium (IAPC) trial is a randomised, multi-arm study platform to compare the efficacy of experimental therapies versus standard of care in subjects with acute myeloid leukaemia in first complete remission. Domain 2 is investigating the safety and efficacy of Venetoclax as a maintenance therapy alone or in combination with low dose cytarabine (LDAC). (
AMLM22-D2
)
BCL2 inhibitor
antimetabolite
Acute myeloid leukaemia
NT
0810 - Tiwi, Royal Darwin Hospital - Northern Centre for Oncology
NSW
2031 - Randwick - Prince of Wales Hospital
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2139 - Concord - Concord Repatriation General Hospital
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2640 - Albury - Border Medical Oncology Research Unit
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
WA
6000 - Perth - Royal Perth Hospital
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
6150 - Murdoch - Fiona Stanley Hospital
TAS
7000 - Hobart - Royal Hobart Hospital
7250 - Launceston - Launceston General Hospital - Northern Cancer Centre
NCT03994393
Advanced
Phase 2
Unknown
A Phase 2 Trial of Durvalumab (MEDI4736) and Tremelimumab With Chemotherapy in Metastatic EGFR Mutant Non-squamous Non-small Cell Lung Cancer (NSCLC) Following Progression on EGFR Tyrosine Kinase Inhibitors (TKIs) (
ILLUMINATE
)
anti-CTLA-4 monoclonal antibody
anti-PD-L1 monoclonal antibody
EGFR-mutant non-small cell lung cancer
Non-small cell lung cancer
NSW
2170 - Liverpool - Liverpool Hospital
2217 - Kogarah - St George Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3065 - Fitzroy - St Vincent's Hospital Melbourne
3168 - Clayton - Monash Medical Centre
QLD
4032 - Chermside - The Prince Charles Hospital
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
TAS
7000 - Hobart - Royal Hobart Hospital
NCT02773524
Advanced
Phase 3
Unknown
A Randomised Phase III Double-Blind Placebo-Controlled Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer (AGOC) (
INTEGRATEIIa
)
KIT/PDGFR/RET/VEGFR/FGFR inhibitor
placebo
Gastroesophageal cancer
NT
0810 - Tiwi, Royal Darwin Hospital - Northern Centre for Oncology
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2031 - Randwick - Prince of Wales Hospital
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2139 - Concord - Concord Repatriation General Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2217 - Kogarah - St George Hospital
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
2305 - New Lambton Heights - Newcastle Private Hospital
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute
2485 - Tweed Heads - The Tweed Hospital
2640 - Albury - Border Medical Oncology Research Unit
ACT
2605 - Garran - The Canberra Hospital
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
3355 - Wendouree - Ballarat Oncology & Haematology Clinical Trials Unit
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4575 - Birtinya - Sunshine Coast University Hospital
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5011 - Woodville South - The Queen Elizabeth Hospital
5035 - Ashford - Flinders Medical Centre, Ashford Cancer Centre Research
5042 - Bedford Park - Flinders Medical Centre
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
TAS
7000 - Hobart - Royal Hobart Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT02582697
Advanced
Phase 3
Unknown
Phase 3 Accelerated BEP: A Randomised Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours (
P3BEP
)
Bleomycin
Cisplatin
Etoposide
Filgrastim
Pegfilgrastim
antineoplastic antibiotic
cancer therapy
cytotoxic chemotherapy
platinum-based antineoplastic agent
topoisomerase inhibitor
Germ cell tumour
NSW
2031 - Randwick - Prince of Wales Hospital
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2076 - Wahroonga - Sydney Adventist Hospital
2109 - North Ryde - Macquarie University Hospital
2139 - Concord - Concord Repatriation General Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2485 - Tweed Heads - The Tweed Hospital
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (WITHDRAWN)
VIC
3002 - Melbourne - Peter MacCallum Cancer Centre, East Melbourne campus
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
3690 - Wodonga - Border Medical Oncology at Wodonga Regional Cancer Centre
3021 - St Albans - Western Health - Sunshine Hospital (WITHDRAWN)
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4101 - South Brisbane - Queensland Children's Hospital
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Flinders Medical Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
TAS
7000 - Hobart - Royal Hobart Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.1023 - Grafton - Starship Children's Hospital
NZ.4442 - Roslyn - Palmerston North Hospital Cancer Centre - Palmerston North Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NZ.9016 - Dunedin - Dunedin Hospital (WITHDRAWN)
ACTRN12621001347853
Advanced
Phase 2
*recruitment paused
A phase 2, open-label, single-arm sulfasalazine monotherapy trial of progression-free survival in patients with pancreatic adenocarcinoma (
SPEAR
)
SLC7A11 inhibitor
Pancreatic cancer
NSW
2076 - Wahroonga - Sydney Adventist Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3066 - Epping - Northern Hospital
3121 - Richmond - Epworth Freemasons Hospital
QLD
4215 - Southport - Gold Coast University Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
TAS
7000 - Hobart - Royal Hobart Hospital
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (23)
Unknown (3)
Enrolling by invitation (1)
Not yet recruiting (1)
Not yet recruiting (1)
*recruitment paused (1)
Recruitment Country and State
TAS (29)
VIC (28)
NSW (27)
QLD (27)
SA (24)
WA (19)
NZ (8)
ACT (5)
NT (4)
Phase
Phase 1 (1)
Phase 1 / Phase 2 (2)
Phase 2 (11)
Phase 3 (15)
Trial Type
Haem (15)
Advanced (12)
Curative (3)
Cancer Therapy Class
PD-1/PD-L1
23%
PD-L1
13%
PD-1
10%
BTK
10%
CD20
10%
cereblon
10%
XPO1
10%
TIGIT
7%
CD79b
7%
proteasome
7%
oestrogen axis
7%
CTLA4
7%
PI3Kalpha
7%
AR
3%
CYP17A1
3%
androgen axis
3%
BCMA
3%
CS1
3%
ER
3%
CD19
3%
telomerase
3%
IL-6
3%
PARP
3%
PI3K-delta
3%
PI3K
3%
mTOR
3%
mTORC1
3%
mTORC2
3%
HRAS G12C
3%
KRAS
3%
KRAS G12C
3%
NRAS G12C
3%
VEGF
3%
CD38
3%
CD47
3%
CDK4
3%
CDK6
3%
ATR
3%
WEE1
3%
IDH1
3%
IDH1 R132
3%
IDH2
3%
BCL2
3%
FGFR
3%
FGFR1
3%
FGFR1/2/3
3%
FGFR2
3%
FGFR3
3%
FGFR4
3%
KIT
3%
PDGFR
3%
RET
3%
VEGFR
3%
SLC7A11
3%
Facility
7000 - Hobart - Royal Hobart Hospital (30)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (17)
3000 - Melbourne - Peter MacCallum Cancer Centre (15)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (13)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (13)
5042 - Bedford Park - Flinders Medical Centre (13)
3168 - Clayton - Monash Medical Centre (13)
4102 - Woolloongabba - Princess Alexandra Hospital (11)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (11)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (10)
2050 - Camperdown - Chris O'Brien Lifehouse (10)
2139 - Concord - Concord Repatriation General Hospital (10)
3066 - Epping - Northern Hospital (10)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (10)
3004 - Melbourne, Southbank - Alfred Health (9)
6150 - Murdoch - Fiona Stanley Hospital (8)
3128 - Box Hill - Box Hill Hospital - Eastern Health (8)
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong (8)
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital (8)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (8)
2031 - Randwick - Prince of Wales Hospital (7)
2640 - Albury - Border Medical Oncology Research Unit (7)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (7)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (6)
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital (6)
3065 - Fitzroy - St Vincent's Hospital Melbourne (6)
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute (5)
7250 - Launceston - Launceston General Hospital - Northern Cancer Centre (5)
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital (5)
2170 - Liverpool - Liverpool Hospital (5)
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre (4)
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit (4)
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre (4)
0810 - Tiwi, Royal Darwin Hospital - Northern Centre for Oncology (4)
5011 - Woodville South - The Queen Elizabeth Hospital (4)
2605 - Garran - The Canberra Hospital (4)
3021 - St Albans - Western Health - Sunshine Hospital (4)
4575 - Birtinya - Sunshine Coast University Hospital (4)
6000 - Perth - Royal Perth Hospital (4)
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (4)
2076 - Wahroonga - Sydney Adventist Hospital (3)
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (3)
5037 - Kurralta Park - Icon Cancer Centre Adelaide (3)
4350 - Toowoomba - Toowoomba Hospital (3)
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital (3)
4215 - Southport - Gold Coast University Hospital (3)
2217 - Kogarah - St George Hospital (3)
3011 - Footscray - Footscray Hospital (3)
NZ.9016 - Dunedin - Dunedin Hospital (3)
2485 - Tweed Heads - The Tweed Hospital (3)
2109 - North Ryde - Macquarie University Hospital (2)
2560 - Campbelltown - Macarthur Cancer Therapy Centre - Campbelltown Hospital (2)
5112 - Elizabeth Vale - Lyell McEwin Hospital (2)
2200 - Bankstown - Bankstown-Lidcombe Hospital (2)
3844 - Traralgon - Latrobe Regional Hospital (2)
2305 - New Lambton Heights - Newcastle Private Hospital (2)
3199 - Frankston - Peninsula Health Frankston Hospital (2)
3121 - Richmond - Epworth Freemasons Hospital (2)
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital (2)
NZ.0622 - Takapuna - North Shore Hospital (2)
NZ.3112 - Tauranga - Tauranga Hospital, Bay of Plenty Clinical Trials Unit (2)
4032 - Chermside - The Prince Charles Hospital (2)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (2)
NZ.4442 - Roslyn - Palmerston North Hospital Cancer Centre - Palmerston North Hospital (2)
4120 - Greenslopes - Greenslopes Private Hospital- Gallipoli Medical Research Foundation (1)
4215 - Southport - Tasman Oncology (1)
6005 - West Perth - Perth Blood Institute (1)
4812 - Hyde Park - Icon Cancer Centre Townsville (1)
4700 - Rockhampton - Rockhampton Hospital (1)
4870 - Cairns - Cairns Base Hospital (1)
6009 - Nedlands - One Clinical Research (1)
4215 - Southport - ICON Cancer Care (1)
3002 - East Melbourne - Epworth Freemasons (1)
2060 - North Sydney - Mater Hospital (1)
3135 - Ringwood East - Maroondah Hospital (1)
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital (1)
3630 - Shepparton - Goulburn Valley Health (1)
4655 - Urraween - Cancer Care Service, Hervey Bay Hospital (1)
4740 - Mackay - Mackay Base Hospital (1)
2487 - Cudgen - Tweed Valley Hospital (1)
2640 - Albury - Albury Wodonga Regional Cancer Centre (1)
2606 - Canberra - Paratus Clinical Research Woden (1)
4120 - Greenslopes - Brisbane Clinic For Lymphoma, Myeloma And Leukaemia (1)
4224 - Tugun - Genesis Care Tugun - John Flynn Private Hospital (1)
NZ.3210 - Hamilton - Waikato Hospital (1)
2086 - Frenchs Forest - Northern Beaches Hospital (1)
4217 - Benowa - Pindara Private Hospital (1)
2305 - New Lambton Heights - Hunter New England Cancer Centre - John Hunter Hospital (1)
2500 - Wollongong - Wollongong Hospital (1)
2480 - Lismore - Lismore Base Hospital (1)
2025 - Papatoetoe - Middlemore Hospital
2340 - Tamworth - Tamworth Hospital-North West Cancer Centre (1)
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health (1)
3355 - Wendouree - Ballarat Oncology & Haematology Clinical Trials Unit (1)
5035 - Ashford - Flinders Medical Centre, Ashford Cancer Centre Research (1)
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital (1)
3002 - Melbourne - Peter MacCallum Cancer Centre, East Melbourne campus (1)
3690 - Wodonga - Border Medical Oncology at Wodonga Regional Cancer Centre (1)
4101 - South Brisbane - Queensland Children's Hospital (1)
NZ.1023 - Grafton - Starship Children's Hospital (1)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (1)
Cancer Type
Cancer
Solid tumour
Haematological malignancy
B-cell malignancy
B-cell lymphoma
Lymphoma
Mature B-cell malignancy
Non-Hodgkin's lymphoma
Thoracic cancer
High-grade B-cell lymphoma
Multiple myeloma
Plasma cell disorder
Lung cancer
Non-small cell lung cancer
Respiratory tract cancer
Diffuse large B-cell lymphoma
Leukaemia
Gynaecological cancer
Gastrointestinal cancer
Upper gastrointestinal cancer
Urogenital cancer
Endometrial cancer
Myeloproliferative neoplasm
Gastroesophageal cancer
Epithelial Ovarian Cancer
Fallopian tube cancer
High-grade serous carcinoma of the ovary, fallopian tube, and peritoneum
Ovarian cancer
Primary fallopian tube serous carcinoma
Acute myeloid leukaemia
Myeloid leukaemia
Castrate-resistant prostate cancer
Male genital cancers
Prostate adenocarcinoma
Prostate cancer
Chronic lymphocytic leukaemia
Lymphoid leukaemia
Small Lymphocytic Lymphoma
Breast cancer
Follicular lymphoma
Myelofibrosis
Anaplastic astrocytoma
Central nervous system cancer
Glioma
High-grade glioma
Low-grade glioma
Malignant glioma
Neurological cancer
Non-squamous non-small-cell lung cancer
Gastric adenocarcinoma
Gastric cancer
Gastric carcinoma
Gastroesophageal junction adenocarcinoma
Oesophageal cancer
Carcinoma
Endometrial stromal sarcoma
High-grade serous ovarian cancer
Leiomyosarcoma
Low-grade serous ovarian cancer
Ovarian adenocarcinoma
Ovarian granulosa cell tumour
Ovarian serous carcinoma
Platinum resistant high-grade epithelial cancers of fallopian tube
Platinum resistant ovarian cancer
Sarcoma
Sex cord-gonadal stromal tumour
Soft tissue sarcoma
Uterine leiomyosarcoma
Myelodysplastic syndrome
EGFR-mutant non-small cell lung cancer
Germ cell tumour
Pancreatic cancer
Pancreatobiliary cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy